Interleukin Genetics Announces Conference Call to Discuss Second Quarter 2016 Financial Results

WALTHAM, Mass., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Interleukin Genetics, Inc. (OTCQB:ILIU) announced today that it will host a conference call and webcast on Tuesday, August 16, 2016, at 8:30 a.m. Eastern Time to provide a corporate update and discuss the Company’s financial results for the second quarter ended June 30, 2016.

Tuesday, August 16th, 8:30 a.m. Eastern Time
Dial in (domestic): 877-324-1976
Dial in (international): 631-291-4550
Conference ID: 62562552

A live webcast will also be available at the Investors section of the Company’s website at The webcast will be archived following the call at

About Interleukin Genetics
Interleukin Genetics, Inc. (OTCQB:ILIU) develops and markets proprietary genetic tests for chronic inflammatory diseases and health-related conditions, with significant expertise in metabolism and inflammation. Our tests provide information that is not otherwise available to empower individuals and their healthcare providers to manage their health and wellness through genetics-based insights and actionable guidance. Interleukin Genetics leverages its research, intellectual property, and genetic panel development expertise in inflammation and metabolism to identify individuals whose risk for certain chronic disease may be increased due to variants in one or more genes, which can enable a more targeted approach to the individual’s healthcare. The company markets its tests through healthcare professionals, partnerships with health and wellness companies, and other distribution channels. Interleukin Genetics’ lead products include its proprietary PerioPredict® genetic test that identifies individuals at risk for severe periodontal disease and a life-long predisposition to overproduce inflammation, and its Inherent Health® line of genetic tests. Interleukin Genetics is headquartered in Waltham, MA and operates an on-site, state-of-the-art DNA testing laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). For more information, please visit

Investor Contact: Hans Vitzthum LifeSci Advisors, LLC. (212) 915-2568 Media Contact: Jennifer Moritz Zer0 to 5ive for Interleukin Genetics (917) 748-4006

Source:Interleukin Genetics, Inc.